• Elicio Announces IND for Vaccine Targeting Mutated KRAS Cancers americanpharmaceuticalreview
    March 01, 2021
    Elicio Therapeutics has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for ELI-002. ELI-002 is an Amphiphile (AMP) KRAS therapeutic vaccine containing AMP mKRAS peptides and a proprietary AMP CpG ...
PharmaSources Customer Service